FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology and radiation diagnostics, and can be used to assess the regional prevalence of breast cancer using single-photon emission computed tomography. Radiopharmaceutical is made just before its intravenous administration. To do this, 4 ml of sodium pertechnetate Na99mTcO4 is injected under aseptic conditions with a syringe from the generator to the reagent vial. Composition of the reagent is as follows: 1-thio-D-glucose sodium salt hydrate - 0.625 mg, tin 2-water dichloride - 0.044–0.052 mg, ascorbic acid - not more than 0.125 mg, sodium chloride 8.0–10.0 mg, water for injection - up to 1 ml. Contents of the vial is mixed by shaking and incubated at room temperature for 30 minutes until complete dissolution of the reagent. Resulting radiopharmaceutical is injected on the basis of technetium-99m labelled derivative of glucose at a dose of 500 MBq. 40 minutes after radiopharmaceutical injection, single-photon emission computed tomography is performed on a two-detector gamma camera. Resulting images are post-processed. Metastatic lesion of regional lymph nodes is diagnosed when imaging radiotherapy sites of radiopharmaceuticals in axillary regions.
EFFECT: method provides improved accuracy and informative assessment of regional prevalence of breast cancer through the use of radiopharmaceuticals based on technetium-99m labelled derived of glucose and single-photon emission computed tomography.
1 cl, 1 dwg, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF RADIONUCLIDAL DIAGNOSTICS OF LARYNGEAL AND PHARYNGOPHARYNGEAL CANCER | 2017 |
|
RU2679298C1 |
METHOD OF RADIONUCLIDAL DIAGNOSTICS OF BREAST CANCER | 2017 |
|
RU2682880C1 |
METHOD FOR ASSESSING THE EFFECTIVENESS OF CHEMOTHERAPY FOR MALIGNANT LYMPHOMAS | 2019 |
|
RU2700105C1 |
METHOD FOR RADIONUCLIDE DIAGNOSTICS OF MALIGNANT LYMPHOMAS | 2018 |
|
RU2706602C1 |
METHOD FOR RADIONUCLIDE DIAGNOSTICS OF LUNG CANCER | 2020 |
|
RU2751103C1 |
COLON CANCER DIAGNOSIS METHOD | 2021 |
|
RU2755010C1 |
METHOD FOR RADIONUCLIDE DIAGNOSING OF CEREBRAL TUMORS | 2017 |
|
RU2692451C2 |
METHOD FOR RADIONUCLIDE DIAGNOSING OPERABLE BREAST CANCER WITH OVEREXPRESSION OF HER2/NEU | 2019 |
|
RU2702294C1 |
METHOD FOR RADIONUCLIDE DIAGNOSIS OF PROSTATE CANCER | 2021 |
|
RU2776234C1 |
METHOD OF BREAST CANCER DIAGNOSTICS WITH HER2/NEU HYPEREXPRESSION | 2022 |
|
RU2800818C1 |
Authors
Dates
2019-02-06—Published
2017-10-02—Filed